This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berman, J D Articles by Lopez-Berestein, G Search for Related Content PubMed PubMed Citation Articles by Berman, J D Articles by Lopez-Berestein, G

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1986 December; 30(6): 847-851

Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.

J D Berman, W L Hanson, W L Chapman, C R Alving and G Lopez-Berestein

ABSTRACT

Visceral leishmaniasis (kala-azar) results from parasitization of the macrophages of the liver, spleen, and the rest of the visceral reticuloendothelial system with Leishmania donovani. Pentavalent antimony is the drug of choice for leishmaniasis chemotherapy; amphotericin B (AmB) is active but is rarely used, because of drug toxicity. AmB encapsulated within macrophage-directed carriers (liposomes) has been used to treat humans with systemic mycoses complicating neoplastic diseases; dosages of up to 5 mg of encapsulated AmB per kg per day for greater than 14 days are without apparent kidney or liver toxicity. In the present work, greater than 99% of L. donovani parasites were eliminated from the liver and spleen of infected hamsters by one administration of 1.5 to 11 mg of liposome-encapsulated AmB (L-Amb) per kg. A total of 98 to 99% of hepatosplenic parasites were eliminated from squirrel monkeys by three administrations of 4 mg of L-AmB per kg. L-AmB was 170 to 750 times as active as antimony in hamsters, and approximately 60 times as active as antimony in monkeys. The demonstration that apparently nontoxic human dosages of L-AmB eliminate essentially all hepatosplenic parasites in hamster and primate models suggests that this preparation should be considered for clinical trial against kala-azar.

---

Antimicrob Agents Chemother. 1986 December; 30(6): 847-851

This article has been cited by other articles:

• Banerjee, A., De, M., Ali, N. (2008). Complete Cure of Experimental Visceral Leishmaniasis with Amphotericin B in Stearylamine-Bearing Cationic Liposomes Involves Down-Regulation of IL-10 and Favorable T Cell Responses. J. Immunol. 181: 1386-1398 [Abstract] [Full Text]  
• Maes, L., Germonprez, N., Quirijnen, L., Van Puyvelde, L., Cos, P., Vanden Berghe, D. (2004). Comparative Activities of the Triterpene Saponin Maesabalide III and Liposomal Amphotericin B (AmBisome) against Leishmania donovani in Hamsters. Antimicrob. Agents Chemother. 48: 2056-2060 [Abstract] [Full Text]  
• Laguna, F., Videla, S., Jimenez-Mejias, M. E., Sirera, G., Torre-Cisneros, J., Ribera, E., Prados, D., Clotet, B., Sust, M., Lopez-Velez, R., Alvar, J. (2003). Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 52: 464-468 [Abstract] [Full Text]  
• Murray, H. W. (2001). Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis. Antimicrob. Agents Chemother. 45: 2185-2197 [Full Text]  
• Petit, C., Yardley, V., Gaboriau, F., Bolard, J., Croft, S. L. (1999). Activity of a Heat-Induced Reformulation of Amphotericin B Deoxycholate (Fungizone) against Leishmania donovani. Antimicrob. Agents Chemother. 43: 390-392 [Abstract] [Full Text]